Nuvation Bio 2nd Quarter Results

Nuvation Bio (NUVB) is addressing unmet medical need in cancer with lead approved drug Ibtrozi, and clinical testing Safusidenib for high grade glioma. The company released second quarter financial results before market open today. The company is gaining traction with new patients for lead drug Ibtrozi. The drug has been FDA approved for ROS1 NSCLC since June of 2025, and revenues are starting to climb. Some key highlights from the second quarter results below. 

- $31.7 million in second quarter total revenue

- $23.2 Ibtrozi US revenue

- 30% quarter over quarter TKI naive growth

- License and collaboration revenue of $8.5 million

- Convertible senior notes raised $279 million in Q2

- Cash equivalents of $697 million

- Current Market cap of $2.3B

The net loss was $62.8 million for the quarter, or (.18) per share.

Second drug Safusidenib is currently in phase 3 testing with the SIGMA trial for glioma, with expected completion around 2029. The trial can be viewed here NCT05303519. 

All prior Nuvation posts can be viewed here Nuvation Bio Posts. Thank you for reading.

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes only, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.

NUVB: Nuvation Bio Update #12

Nuvation Bio has one commercial asset Ibtrozi for ROS1 NSCLC. Their second asset Safusidenib for high-grade glioma, is in clinical trials which can be found here Clinical Trials. The latest positive news from Nuvation comes as they have received net proceeds of $277.6 million, from an oversubscribed convertible notes offering due 2032. Positives from the just completed notes offering below. 

• Retired older, high interest debt of $55.8 million
• $17.1 million used for capped call options, hedge to $10.458 
• At present, is non-diluting to shareholders
• Added new cash of around $205 million after all deductions
• Multi-year cash runway now available

The new cash infusion will be used to fund clinical development, and general corporate purposes. Weekly chart of Nuvation below, thank you for reading.

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes only, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.

NUVB: Nuvation Bio Update #11

All of Nuvation Bio's previous posts, can be found here Nuvation Posts.  The company is addressing the unmet need of ROS1 and high grade glioma, with two unique drugs. 

From recent investor conferences that the company has participated, we were given some updated pipeline information. Two updates of interest, include the following for second drug candidate safusidenib. 

1. The 40 patient Grade 3 oligodendroglioma which is part of the SIGMA study NCT05303519, has objective response rate as the primary endpoint. The goal of achieving a 20% + response rate in this population, would be seen as positive over standard of care chemotherapy for these patients. The study will be conducted as an Open-Label single arm. 

 2. Yet To Be Announced: Safusidenib treatment for those patients that have been on approved drug vorasidenib, and over time have failed. The endpoint again would be objective response rate, with a goal of achieving 20%. 

 

Both trials could benefit from ORR as a quicker endpoint read-out, a smaller number of patients, with potential 2027 data. The daily chart of Nuvation below displays a consolidation range over the past two and a half months. The high of $5.29 and low support at $4.05. This consolidation chart pattern has the potential to have a strong breakout.  

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes only, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.

NUVB: Nuvation Bio Update #10

Nuvation Bio is addressing unmet medical need in cancer with lead approved drug Ibtrozi, and clinical testing Safusidenib for high grade glioma. The company released first quarter financial results after the close of trading today. The company is gaining traction with new patients for lead drug Ibtrozi. The drug has been FDA approved for ROS1 NSCLC since June of 2025. Some key highlights from the first quarter results below. 

- 18.5 million in first quarter Ibtrozi revenue

- Greater than 50% of new patients were early line diagnosis

- China / Japan royalty revenue of $1.7 million

- Cash equivalents of $533.7 million

- Current Market cap of $1.5B

Essentially it was a breakeven quarter for Nuvation due to a one time collaboration payment from European partner Eisai, which combined with quarterly revenue, covered the research and SGA costs for the quarter. 

Second drug Safusidenib is currently in phase 3 testing with the SIGMA trial for high grade glioma, with expected completion around 2029. The trial can be viewed here NCT05303519. 

All prior Nuvation posts can be viewed here Nuvation Bio Posts. Thank you for reading. 

NUVB: Nuvation Bio - Update #9

Nuvation Bio held their 4th quarter conference call today to update investors, on the progress of their cancer drug development programs. Just some key points below, as they will be a multi-year investment, with updates along the way.

• 4th quarter revenue of $41 million, a combination of product and license
• Net loss of $36 million, or 0.11 cents per share with 344 million shares outstanding
• The company is well funded with $529 million in cash and equivalents
• Partner Eisai to file for Ibtrozi ROS1 approval in EU by mid-year 2026
• SIGMA safusidenib 40 patient exploratory cohort, grade 3 oligodendroglioma study with readout expected in 2027
• No revenue guidance announced by the company at this time

The stock has been stable, trading in the $5.00 to $6.00 per share range in the last month, with chart below.  Thank you for reading.

NUVB: Nuvation Bio - Update #8

Nuvation Bio has updated investors with the good news of a European partnership, to sell newly FDA approved and commercialized drug Ibtrozi in Europe and other countries outside of the US, for patients with Ros1 NSCLC. Like many other US based companies, they utilize partnerships outside the US who already have a footprint of sales professionals actively selling similar products in the field. Under this agreement completed today with Eisai, there is upfront, milestones and a royalty kick back to the owner of the product, in this case Nuvation Bio. The selling partner reaps the revenue abroad. A win / win cost effective scenario. Below are the Royalty agreements that are now in place outside of the US for Nuvation Bio (NUVB). 

China: Innovent Biologics 
(Dovbleron) First and second-line approval.

-Milestone payments up to $189 million

-Tiered royalty payments based on annual net sales of Taletrectinib

Europe: Eisai

-60 million upfront 

-170 million milestone payments

-10% to 19% tiered royalty payments from net sales of Taletrectinib

Japan: Nippon Kayaku
-Milestone payments based on domestic sales exceeding certain amounts

-Royalty based on domestic net sales

NUVB: Nuvation Bio - Update #7

Past Nuvation Bio posts can be found in date order, by clicking here Nuvation Bio. 

There are different ways to calculate a stock price target. One way is to use a comparison valuation method. This post considers the current market valuation ($2.932 billion) for Nuvation Bio. 

For comparison valuation; In June of 2022 Bristol Myer Squibb offered 4.1 billion to buy Turning Point Therapeutics for their lead drug candidate Repotrectinib a TKI inhibitor for the same indication that Nuvation has been FDA approved for ROS1 NSCLC, BMS News. 

Their interest was lead drug Repotrectinib for ROS1 NSCLC. At the time Repotrectinib had only completed phase 1/2 testing of the drug, and not FDA approved, until 11/23, then again 6/24 for NTRK gene-fusion positive tumors.

 

If we were to apply the 4.1 billion that Turning Point was acquired for, and relate it to NUVB today, it would calculate out to $4100B / 343m shares outstanding = $11.95 per share price target.

- Keeping in mind that Nuvation's lead drug Ibtrozi has already received FDA approved for ROS1 NSCLC and has a global footprint in place to distribute the drug, something that Turning Point did not have at the time of acquisition by BMS.

- Nuvation has already achieved revenues for newly approved Ibtrozi. 

- This comparison is void of any efficacy discussions of Ibtrozi vs Repotrectinib, which should be viewed in another post altogether.

- Nuvation's second drug candidate Safusidenib has entered pivotal phase 3 testing for another unmet need, in glioma.

 

Comparison's can be tricky, but in this case, I would consider the $11.95 stock price of Nuvation Bio ($4.1 billion valuation) the minimum price target, based on this comparison. Chart below, thank you for reading. 

NUVB: Nuvation Bio - Update #6

This morning Nuvation Bio gave investors a nice update of 3rd quarter financial results. In just their first quarter of commercialization with the FDA approved drug Ibtrozi (taletrectinib) for ROS1 NSCLC, the company achieved 7.7 million in total revenue. The company also guided on their pipeline which includes oral drug Safusidenib for IDH1 high-grade gliomas. Key points of progress in the 3rd quarter report and conference call. 

Ibtrozi (taletrectinib)

• Ibtrozi 3rd quarter sales of $7.7 million 
• Ibtrozi DOR (duration of response) has reached 50 months

Safusidenib

• Begin Phase 3 Safusidenib maintenance treatment high-grade 3 or 4 gliomas
• No other market entrants have been approved for high-grade gliomas
• Global phase 3 safusidenib trial has registrational potential

NUV-1511

• Clinical trial update 4th quarter

Financial

• $549 million cash on hand, end of 3rd quarter
• $25 million milestone payment fourth quarter
• 543 million shares outstanding

NUVB: Nuvation Bio - Update #5

A purely technical post regarding Nuvation Bio (NUVB). Technical analysis is the practice of using historical data and current price action, to predict future price movements. Since March of 2024 the stock has hit the $4.00 ceiling level and has turned back down on three occasions. It could be investors taking profits, or short sellers looking for opportunity at that level. NUVB finally broke out higher of that level this week, bringing in new technical strength of higher prices to the stock, chart below. The company will report third quarter earning's on November 3rd, when we'll get the fundamental investment details. 

 

NUVB: Nuvation Bio - Update #4

Nuvation Bio's (NUVB) recently FDA approved drug (taletrectinib) known commercially as Ibtrozi, has only been on the market for three month's since approval in June. Expectations for revenues are now just being released by research firms. S&P Global has released an estimated revenue projection for Ibtrozi for ROS1-positive non-small cell lung cancer (NSCLC), versus it's competitors in the same space. Graph below is from Visible Alpha, part of S&P Global market intelligence. The entire article can be viewed here ROS1 Lung Cancer Market.

NUVB: Nuvation Bio - Update #3

An update on Nuvaton Bio's progress the past few months, as the company and stock have been performing well since receiving FDA approval of Taletrectinib, a drug for ROS1-positive non small cell lung cancer (NSCLC). Another drug in their pipeline NUV-1511 is in clinical studies for five indications. 

 Financial Statistics: 

• $608 million cash
• Debt - minimal
• 341 million diluted shares outstanding
• 938 million market cap

Intellectual Property:

• Taletrectinib - Expected to expire from 2033 to 2042
• Safusidenib - Expected to expire from 2035 to 2041
• NUV-1511 - Expected to expire 2039 to 2043

Nuvation Bio's pipeline includes NUV-1511 a drug known as a DCC (drug-drug conjugate), which is in a phase 1/2 being tested for patients with advanced solid tumors in five separate indications here NUV-1511. This large study will include 466 patients to conclude in early 2027. The company expects more details forthcoming. Weekly chart below of Nuvation, thank you for reading. 

NUVB: Nuvation Bio - Update #2

Today, Nuvation Bio's lead drug candidate Taletrectinib was approved for ROS1-Positive Non- Small Cell Lung Cancer. This is good news for cancer patients, good for the company and investors alike. The full press release from Nuvation Bio is here FDA Approval Press Release.  The newly commercialized product name, will be Ibtrozi. Thank you for reading.

NUVB: Nuvation Bio - Update #1

Nuvation Bio's (NUVB) Taletrectinib is currently in FDA review for Advanced ROS1-Positive NSCLC, with a decision date (PDUFA) of June 23rd. Taletrectinib a (tyrosine kinase inhibitor) TKI, could potentially become an effective treatment for another indication such as Colorectal Cancer (CRC). This paper from Nature with several scientists contributing, have completed a study in vitro using two CRC cell lines, and in vivo in a mouse model. The articles thesis is that Taletrectinib promotes pyroptosis in colorectal carcinoma, via SRC/AKT/mTOR axis inhibition. Nuvation Bio is a high risk investment at this time, as they have zero commercial assets, and are awaiting an FDA decision for their lead drug Taletrectinib. Chart below of Nuvation Bio, thank you for reading. 

NUVB: Nuvation Bio

Nuvation Bio, a development-stage oncology company, focuses on the clinical development for the treatment of cancer. The companies lead drug Taletrectinib, an orally available inhibitor is currently being reviewed by the FDA for Advanced ROS1+NSCLC, with a decision date (PDUFA) of June 23rd. 

Financial Statistics: 

• $461 million cash
• Debt - minimal
• 340 million diluted shares outstanding
• 782 million market cap

Intellectual Property:

• Taletrectinib - Expected to expire from 2033 to 2042
• Safusidenib - Expected to expire from 2035 to 2041

Timeline Catalyst:

• Taletrectinib: FDA approval decision June 23, 2025
• Safusidenib: Begin pivotal phase 3 for diffuse IDH1-mutant glioma, 2025